S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
The Market Crash Shield is A.I. (Ad)pixel
MarketBeat Week in Review – 3/27 - 3/31
UK travelers face hours-long waits for ferries to France
The Market Crash Shield is A.I. (Ad)pixel
UN body mulls deep sea mining amid demand for minerals
Credit Suisse takeover hits heart of Swiss banking, identity
3 Secrets To Consistent Trading Success (Ad)pixel
Intensity and insults rise as lawmakers debate debt ceiling
Canada approves largest telecom deal in country's history
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
The Market Crash Shield is A.I. (Ad)pixel
MarketBeat Week in Review – 3/27 - 3/31
UK travelers face hours-long waits for ferries to France
The Market Crash Shield is A.I. (Ad)pixel
UN body mulls deep sea mining amid demand for minerals
Credit Suisse takeover hits heart of Swiss banking, identity
3 Secrets To Consistent Trading Success (Ad)pixel
Intensity and insults rise as lawmakers debate debt ceiling
Canada approves largest telecom deal in country's history
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
The Market Crash Shield is A.I. (Ad)pixel
MarketBeat Week in Review – 3/27 - 3/31
UK travelers face hours-long waits for ferries to France
The Market Crash Shield is A.I. (Ad)pixel
UN body mulls deep sea mining amid demand for minerals
Credit Suisse takeover hits heart of Swiss banking, identity
3 Secrets To Consistent Trading Success (Ad)pixel
Intensity and insults rise as lawmakers debate debt ceiling
Canada approves largest telecom deal in country's history
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
The Market Crash Shield is A.I. (Ad)pixel
MarketBeat Week in Review – 3/27 - 3/31
UK travelers face hours-long waits for ferries to France
The Market Crash Shield is A.I. (Ad)pixel
UN body mulls deep sea mining amid demand for minerals
Credit Suisse takeover hits heart of Swiss banking, identity
3 Secrets To Consistent Trading Success (Ad)pixel
Intensity and insults rise as lawmakers debate debt ceiling
Canada approves largest telecom deal in country's history
NASDAQ:BLFS

BioLife Solutions - BLFS Stock Forecast, Price & News

$21.75
+0.97 (+4.67%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$21.00
$22.10
50-Day Range
$19.50
$26.07
52-Week Range
$10.40
$26.96
Volume
405,620 shs
Average Volume
376,771 shs
Market Capitalization
$930.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00

BioLife Solutions MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
37.9% Upside
$30.00 Price Target
Short Interest
Bearish
5.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.20mentions of BioLife Solutions in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$1.78 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.41) to $0.23 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

674th out of 1,004 stocks

Electromedical Equipment Industry

14th out of 24 stocks


BLFS stock logo

About BioLife Solutions (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1987 and is headquartered in Bothell, WA.

Receive BLFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter.

BLFS Stock News Headlines

Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
Lake Street Reaffirms Their Buy Rating on BioLife Solutions (BLFS)
Maxim Group Keeps Their Buy Rating on BioLife Solutions (BLFS)
Q4 2022 BioLife Solutions Inc Earnings Call
Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
BioLife Solutions's Earnings Outlook
BLFS BioLife Solutions, Inc.
BioLife Solutions
Should You Invest in BioLife Solutions (BLFS)?
BioLife Solutions Expands Intellectual Property Estate
See More Headlines
Receive BLFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter.

BLFS Company Calendar

Last Earnings
11/11/2021
Today
4/01/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLFS
Employees
432
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$30.00
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+37.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-149,850,000.00
Pretax Margin
-89.53%

Debt

Sales & Book Value

Annual Sales
$161.76 million
Book Value
$8.52 per share

Miscellaneous

Free Float
41,355,000
Market Cap
$930.25 million
Optionable
Not Optionable
Beta
1.86

Key Executives

  • Michael P. RiceMichael P. Rice
    Chairman & Chief Executive Officer
  • Geraint Phillips
    Senior Vice President-Global Operations
  • Troy WichtermanTroy Wichterman
    Chief Financial Officer
  • Aby J. MathewAby J. Mathew
    Chief Scientific Officer & Executive VP
  • Roderick de Greef
    Director













BLFS Stock - Frequently Asked Questions

Should I buy or sell BioLife Solutions stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BLFS shares.
View BLFS analyst ratings
or view top-rated stocks.

What is BioLife Solutions' stock price forecast for 2023?

2 brokers have issued 1 year price targets for BioLife Solutions' stock. Their BLFS share price forecasts range from $27.00 to $34.00. On average, they anticipate the company's share price to reach $30.00 in the next year. This suggests a possible upside of 37.9% from the stock's current price.
View analysts price targets for BLFS
or view top-rated stocks among Wall Street analysts.

How have BLFS shares performed in 2023?

BioLife Solutions' stock was trading at $18.20 at the beginning of the year. Since then, BLFS shares have increased by 19.5% and is now trading at $21.75.
View the best growth stocks for 2023 here
.

Are investors shorting BioLife Solutions?

BioLife Solutions saw a increase in short interest in March. As of March 15th, there was short interest totaling 2,120,000 shares, an increase of 10.4% from the February 28th total of 1,920,000 shares. Based on an average daily trading volume, of 318,500 shares, the short-interest ratio is currently 6.7 days. Currently, 5.4% of the shares of the stock are sold short.
View BioLife Solutions' Short Interest
.

When is BioLife Solutions' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our BLFS earnings forecast
.

How were BioLife Solutions' earnings last quarter?

BioLife Solutions, Inc. (NASDAQ:BLFS) posted its quarterly earnings results on Thursday, November, 11th. The medical equipment provider reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of $0.02 by $0.21. The medical equipment provider earned $33.80 million during the quarter, compared to analysts' expectations of $31.65 million. BioLife Solutions had a negative net margin of 85.79% and a negative trailing twelve-month return on equity of 6.79%. During the same period in the prior year, the business earned ($0.02) EPS.

What ETFs hold BioLife Solutions' stock?
What guidance has BioLife Solutions issued on next quarter's earnings?

BioLife Solutions updated its FY 2023 earnings guidance on Thursday, March, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $188.00 million-$202.00 million, compared to the consensus revenue estimate of $195.65 million.

What is Mike Rice's approval rating as BioLife Solutions' CEO?

14 employees have rated BioLife Solutions Chief Executive Officer Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among the company's employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 89.0% of employees surveyed would recommend working at BioLife Solutions to a friend.

What other stocks do shareholders of BioLife Solutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM).

What is BioLife Solutions' stock symbol?

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

How do I buy shares of BioLife Solutions?

Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioLife Solutions' stock price today?

One share of BLFS stock can currently be purchased for approximately $21.75.

How much money does BioLife Solutions make?

BioLife Solutions (NASDAQ:BLFS) has a market capitalization of $930.25 million and generates $161.76 million in revenue each year. The medical equipment provider earns $-149,850,000.00 in net income (profit) each year or ($3.26) on an earnings per share basis.

How many employees does BioLife Solutions have?

The company employs 432 workers across the globe.

How can I contact BioLife Solutions?

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The official website for the company is www.biolifesolutions.com. The medical equipment provider can be reached via phone at (425) 402-1400, via email at rdegreef@biolifesolutions.com, or via fax at 425-402-1433.

This page (NASDAQ:BLFS) was last updated on 4/1/2023 by MarketBeat.com Staff